Waning Immunity Against XBB.1.5 Following Bivalent mRNA Boosters
Lasrado, N.; Collier, A.-r.; Miller, J.; Hachmann, N.; Liu, J.; Sciacca, M.; Wu, C.; Anand, T.; Bondzie, E.; Fisher, J.; Mazurek, C.; Patio, R.; Powers, O.; Rodrigues, S.; Rowe, M.; Surve, N.; Ty, D.; Korber, B.; Barouch, D. H.
Show abstract
The SARS-CoV-2 Omicron variant has continued to evolve. XBB is a recombinant between two BA.2 sublineages, XBB.1 includes the G252V mutation, and XBB.1.5 includes the G252V and F486P mutations. XBB.1.5 has rapidly increased in frequency and has become the dominant virus in New England. The bivalent mRNA vaccine boosters have been shown to increase neutralizing antibody (NAb) titers to multiple variants, but the durability of these responses remains to be determined. We assessed humoral and cellular immune responses in 30 participants who received the bivalent mRNA boosters and performed assays at baseline prior to boosting, at week 3 after boosting, and at month 3 after boosting. Our data demonstrate that XBB.1.5 substantially escapes NAb responses but not T cell responses after bivalent mRNA boosting. NAb titers to XBB.1 and XBB.1.5 were similar, suggesting that the F486P mutation confers greater transmissibility but not increased immune escape. By month 3, NAb titers to XBB.1 and XBB.1.5 declined essentially to baseline levels prior to boosting, while NAb titers to other variants declined less strikingly.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine 95%
- Clinical course impacts early kinetics and long-term magnitude and amplitude of SARS-CoV-2 neutralizing antibodies beyond one year after infection 93%
- Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells 93%
Similar papers in this journal
- SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster 95%
- Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains 94%
- Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers 94%
Similar papers in this journal
- mRNA Vaccine-Induced SARS-CoV-2 Spike-Specific IFN-γ and IL-2 T-cell Responses are Predictive of Serological Neutralization and are Transiently Enhanced by Pre-Existing Cross-Reactive Immunity 94%
- NVX-CoV2373 ancestral and NVX-CoV2540 BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters 94%
- A human cytomegalovirus prefusion-like glycoprotein B subunit vaccine elicits similar humoral immunity to that of postfusion gB in mice 93%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.